PDCD1 and neoplasm: Co-overexpression of PD-L1 and PD-L2 (another PD-1 ligand) in the same tumor, as well as overexpression of other co-inhibitory or co-activatory molecules can reliably indicate whether checkpoint blockade is a significant factor in a specific case [42, 43].